ALNYLAM PHARMACEUTICALS, INC.

ALNY

{{popupValue}}
{{popupSubtitle}}

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
ALNY
CIK0001178670
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
Website alnylam.com
Phone(617) 551-8200
CEOYvonne L. Greenstreet
Employees2,000

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$2.35 billion
Pre-Tax Income$-355.38 million
Net Income$-269.70 million
Net Income to Common$-269.70 million
EPS$-2.10
View All
Balance Sheet
Cash$1.02 billion
Assets$4.21 billion
Liabilities$4.10 billion
Common Equity$115.44 million
Liabilities & Equity$4.21 billion
View All
Cash Flow Statement
Calculations
NOPAT$-80.76 million
EBITDA$-273.60 million
Price to EarningsN/A
Price to Book$364.65
ROE519.47%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Exploring Three High Growth Tech Stocks In The US Market

Over the last 7 days, the United States market has risen 2.7% and is up 13% over the last 12 months, with earnings forecasted to grow by 15% annually. In this environment of robust growth, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in an ever-evolving landscape.

Article Link

Exploring 3 High Growth Tech Stocks in the US Market

The United States market has shown positive momentum, climbing 2.7% in the last week and up 13% over the past year, with earnings anticipated to grow by 15% annually in the coming years. In this favorable environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these upward trends.

Article Link

Exploring High Growth Tech Stocks In The US Market

The United States market has experienced a positive trajectory, climbing 1.7% in the last 7 days and showing a 12% increase over the past year, with earnings projected to grow by 15% annually in the coming years. In this environment, identifying high growth tech stocks involves focusing on companies that demonstrate strong innovation capabilities and have robust business models capable of capitalizing on these favorable market conditions.

Article Link

When Will Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Become Profitable?

Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) is possibly approaching a major achievement in its business, so we would...

Article Link

Exploring Three High Growth Tech Stocks in the US Market

The United States market has shown a positive trend, climbing 1.7% in the last week and up 12% over the past year, with earnings projected to grow by 15% annually in the coming years. In this favorable environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to evolving market demands.

Article Link